Gregory Ahearn, MD
Pulmonary Disease · Phoenix, AZNPI 1598772931
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,990 of the $144,119 with a category attached, or 86.0%. United Therapeutics Corporation accounts for 60.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $39,094 and has fallen 99.9% since, to $35 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $750.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$88K
- Actelion Pharmaceuticals US, Inc.$55K
- Inari Medical, Inc.$564
- AbbVie$207
- Sanofi$154
- Merck$136
- plus $433 from 12 others
What the payments were for
- Consulting fees$5,5834%
- Speaking & faculty fees$123,99086%
- Travel & lodging$8,2816%
- Food & beverage$6,2654%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 105 | $87,789 |
| Actelion Pharmaceuticals US, Inc. | 49 | $54,835 |
| Inari Medical, Inc. | 4 | $564 |
| AbbVie | 10 | $207 |
| Sanofi | 3 | $154 |
| Merck | 4 | $136 |
| Bayer | 1 | $113 |
| Boehringer Ingelheim | 3 | $85 |
| AstraZeneca | 2 | $42 |
| Amgen | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Olympus America Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Pulmonx Corporation | 1 | $16 |
| Viiv Healthcare Company | 1 | $16 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENITRAM$59,988
- UPTRAVI$53,446
- OPSUMIT$50,166
- TYVASO$47,589
- REMODULIN$45,587
- NONE$5,465
- FLOWTRIEVER CATHETER, S$515
- CT THROMBECTOMY SYSTEM KIT$515
- DUPIXENT$120
- Adempas$113
How this compares
$144,119 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 32 | $939,386 |
| OpsumitMacitentan | 33 | $431,965 |
| AdempasRiociguat | 26 | $359,678 |
| Ambrisentan | 57 | $205,208 |
| WinrevairSotatercept-Csrk | 12 | $168,363 |
| Tadalafil | 90 | $87,884 |
| AdcircaTadalafil | 15 | $77,389 |
| MounjaroTirzepatide | 17 | $22,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $18,290 |
| OzempicSemaglutide | 19 | $17,933 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $8,187 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $4,918 |
| Sildenafil Citrate | 16 | $1,994 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $933 |
| Montelukast Sodium | 19 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $54,835 | $1,371,35165 claims |
| BayerAdempas | $113 | $359,67826 claims |
| MerckWinrevair | $136 | $168,36312 claims |
| United Therapeutics CorporationAdcirca | $87,789 | $77,38915 claims |
| Boehringer IngelheimStiolto Respimat | $85 | $8,18713 claims |
| AstraZenecaSymbicort | $42 | $4,91825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.